Bispecific dendritic-T cell engager potentiates anti-tumor immunity

Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most patients do not respond to the treatment or suffer from recurrence. We show that the crosstalk between conventional type I dendritic cells (cDC1) and T cells is essential for an effective aPD-1-mediated anti -tumor response. Accordingly, we developed a bispecific DC -T cell engager (BiCE), a reagent that facilitates physical interactions between PD -1+ T cells and cDC1. BiCE treatment promotes the formation of active dendritic/T cell crosstalk in the tumor and tumor -draining lymph nodes. In vivo, single -cell and physical interacting cell analysis demonstrates the distinct and superior immune reprogramming of the tumors and tumor -draining lymph nodes treated with BiCE as compared to conventional aPD-1 treatment. By bridging immune cells, BiCE potentiates cell circuits and communication pathways needed for effective anti -tumor immunity.